Lipid-hydrolyzing enzyme

A "lipid-hydrolyzing enzyme" refers broadly to any member of the **hydrolase** class that catalyzes the breakdown of various types of lipids through hydrolysis—using water to cleave chemical bonds within triglycerides, phospholipids, cholesteryl esters, and related molecules. The most prominent subclasses are **lipases**, which act primarily on triglycerides; **phospholipases**, which target phospholipids involved in membrane remodeling and cell signaling; and specialized enzymes like **lysosomal acid lipase** that regulate intracellular cholesterol/fatty acid balance. These enzymes play critical roles in digestion/absorption of dietary fats, regulation of systemic energy stores, cellular membrane dynamics, signal transduction via bioactive lipid mediators such as endocannabinoids,[6] and clearance/remodeling processes relevant to cardiovascular health. Dysregulation or genetic deficiency leads to diverse pathologies including metabolic syndrome/obesity,[5] rare lysosomal storage diseases,[2] inflammation-related conditions,[6] and increased risk for atherosclerosis/cardiovascular events.[2][5]. Drugs targeting these enzymes either inhibit their action—reducing fat absorption/signaling—or replace missing enzymatic function in inherited deficiencies. Note: "Lipid-hydrolyzing enzyme" is not a single molecular entity but an umbrella term covering multiple distinct proteins with overlapping but non-identical functions. For structured data purposes it should be mapped more specifically when possible—for example "Pancreatic triacylglycerol lipase," "Lysosomal acid lipase," etc.—as each has unique properties relevant to drug discovery/therapeutics.[1][7].

Other names

LipaseFatty acid hydrolaseEsterase (when referring to lipid esters)Phospholipase (for phospholipid substrates)Lysosomal acid lipasePancreatic lipaseHepatic lipaseLipoprotein lipase[8]

Drugs may act by inhibiting the hydrolytic activity on triglycerides or other lipid substrates, thereby reducing absorption or altering cellular lipid signaling. Enzyme replacement therapies restore deficient enzymatic activity in genetic disorders.[2][6]